Moore

Sarah Moore

Associate

Boston

I enjoy helping clients grow from formation to exit by facilitating access to debt and equity financing.

Sarah Moore focuses her practice on advising public and private companies on a wide range of corporate matters, including venture capital financing, debt financing, strategic transactions and general corporate governance matters. 


Education

  • Boston College Law School, J.D., cum laude, 2020
  • Boston College, B.A., cum laude, 2017

Bar and Court Admissions

BAR ADMISSIONS
  • Massachusetts

Experience

  • Burgess BioPower, LLC  and Berlin Station LLC, a biomass energy facility, in their chapter 11 cases filed in Delaware with a restructuring support agreement and plan sponsored by the secured lenders.
  • MDxHealth SA (Nasdaq/Euronext: MDXH), a foreign private issuer, in its acquisition of the OncoType DX Genomic Prostate Score business from Exact Sciences Corporation (Nasdaq: EXAS) for cash and equity consideration of up to $100 million, including a multi-year earn-out arrangement.
  • Ascend Wellness Holdings, Inc., a leading multi-state, vertically integrated cannabis operator
    • in closing on a $50 million private placement of senior secured notes, issued at 97.5% of face value, and a supplemental part of a $235 million debt offering commenced in July and carry an interest rate of 12.75%
    • in closing on a $210 million Senior Secured Term Loan with Seaport Global Securities LLC as lead manager
  • GreenLight Biosciences, a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, in a $1.2 billion SPAC business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI), that will result in GreenLight becoming a publicly listed company

Other Publications

IN THE MEDIA

Honors & Involvement

INVOLVEMENT
  • Foley Hoag Women Associates Affinity Group, Co-Chair

Speaking Engagements

  • "Leading the Change: Women Shaping A Sustainable Future, " Foley Hoag 2026 Women’s History Month Panel (March 2026)